Enlivex Ltd. (ENLV) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Enlivex Ltd. (ENLV) closed at USD 0.22 on 2026-10-14, a change of -98.7 % over the past year, with a market capitalization of USD 4.46M.

Enlivex Ltd. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Enlivex Ltd. key figures

Previous close

USD 0.22 (2026-10-14)

1-year change

-98.7 %

Market cap

USD 4.46M

Enterprise value

USD 15.8M

P/E ratio (trailing)

0.00

P/E ratio (forward)

-0.29

EPS (trailing)

498.67

EPS (forward)

-0.78

PEG ratio

n/a

Price to book

0.00

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.22

Employees

34

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Enlivex Ltd.

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Enlivex Ltd. and compare it with other stocks.